Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
World Journal of Urology
Published in: World Journal of Urology 6/2006

01-12-2006 | Topic Paper

Treatment of sexual dysfunction of hypogonadal patients with long-acting testosterone undecanoate (Nebido®)

Authors: Aksam A. Yassin, Farid Saad

Published in: World Journal of Urology | Issue 6/2006

Login to get access

Abstract

Recently, testosterone undecanoate (TU), a new parenteral testosterone (T) preparation has been introduced. Two of its distinctive features are (a) its prolonged action: after two initial loading injections 6 weeks apart, usually only one injection every 12 weeks is needed (b) over the full interval between two injections, plasma T levels are in the physiological range. New research presents convincing evidence that T has profound effects on tissues of the penis involved in the mechanism of erection and that testosterone deficiency impairs the anatomical and physiological substrate of erectile capacity, which is, at least, in part reversible upon androgen therapy. Our studies with TU demonstrated that venous leakage could be corrected with T treatment in a number of patients. We further could show that sexual functions, in a substantial number of elderly men, can be restored with treatment with T only. So, these results argue for determination of T levels in elderly men with sexual problems. If the levels are subnormal, T treatment is warranted.
Literature
1.
Kaufman JM, Vermeulen A (2005) The decline of androgen levels in elderly men and its clinical and therapeutic implications. Endocrinol Rev 26(6):833–876CrossRefPubMed
2.
Park K, Ku JH, Kim SW, Paick JS (2005) Risk factors in predicting a poor response to sildenafil citrate in elderly men with erectile dysfunction. BJU Int 95(3):366–370CrossRefPubMed
3.
Gray PB, Singh AB, Woodhouse LJ, Storer TW, Casaburi R, Dzekov J (2005) Dose-dependent effects of testosterone on sexual function, mood, and visuospatial cognition in older men. J Clin Endocrinol Metab 90(7):3838–3846CrossRefPubMed
4.
Gooren LJ, Saad F (2006) Recent insights into androgen action on the anatomical and physiological substrate of penile erection. Asian J Androl 8(1):3–9CrossRefPubMed
5.
Yassin AA, Saad F (2006) Dramatic improvement of penile venous leakage upon testosterone administration. A case report and review of literature. Andrologia 38(1):34–37CrossRefPubMed
6.
Yassin AA, Saad F, Traish A (2006) Testosterone undecanoate restores erectile function in a subset of patients with venous leakage: a series of case reports. J Sex Med 3(4):727–735CrossRefPubMed
7.
Schubert M, Minnemann T, Hubler D, Rouskova D, Christoph A, Oettel M (2004) Intramuscular testosterone undecanoate: pharmacokinetic aspects of a novel testosterone formulation during long-term treatment of men with hypogonadism. J Clin Endocrinol Metab 89(11):5429–5434CrossRefPubMed
8.
Harle L, Basaria S, Dobs AS (2005) Nebido: a long-acting injectable testosterone for the treatment of male hypogonadism. Expert Opin Pharmacother 6(10):1751–1759CrossRefPubMed
9.
Behre HM, Wang C, Handelsman DJ, Nieschlag E (2004) Pharmacology of testosterone preparations. In: Nieschlag E, BehreHM (eds) Testosterone, action, deficiency, substitution. Cambridge University Press, UK, pp. 405–444
10.
Dobs AS, Meikle AW, Arver S, Sanders SW, Caramelli KE, Mazer NA (1999) Pharmacokinetics, efficacy, and safety of a permeation-enhanced testosterone transdermal system in comparison with bi-weekly injections of testosterone enanthate for the treatment of hypogonadal men. J Clin Endocrinol Metab 84(10):3469–3478CrossRefPubMed
11.
Behre HM, Abshagen K, Oettel M, Hubler D, Nieschlag E (1999) Intramuscular injection of testosterone undecanoate for the treatment of male hypogonadism: phase I studies. Eur J Endocrinol 140(5):414–419CrossRefPubMed
12.
von Eckardstein S, Nieschlag E (2002) Treatment of male hypogonadism with testosterone undecanoate injected at extended intervals of 12 weeks: a phase II study. J Androl 23(3):419–425
13.
Dobs AS, Matsumoto AM, Wang C, Kipnes MS (2004) Short-term pharmacokinetic comparison of a novel testosterone buccal system and a testosterone gel in testosterone deficient men. Curr Med Res Opin 20(5):729–738CrossRefPubMed
14.
Zitzmann MNE (2006) Long-term experience of more than 8 years with a novel formulation of testosterone undecanoate (Nebido) in substitution therapy of hypogonadal men. Aging Male 9 (suppl 1):5
15.
Nieschlag E, Swerdloff R, Behre HM, Gooren LJ, Kaufman JM, Legros JJ (2005) Investigation, treatment and monitoring of late-onset hypogonadism in males. ISA, ISSAM, and EAU recommendations. Eur Urol 48(1):1–4CrossRefPubMed
16.
Boorjian SA, Bianco FJ Jr, Scardino PT, Eastham JA (2005) Does the time from biopsy to surgery affect biochemical recurrence after radical prostatectomy? BJU Int 96(6):773–776CrossRefPubMed
17.
Graefen M, Walz J, Chun KH, Schlomm T, Haese A, Huland H (2005) Reasonable delay of surgical treatment in men with localized prostate cancer—impact on prognosis? Eur Urol 47(6):756–760CrossRefPubMed
18.
Yassin A, Saad F (2005) Modulation of erectile function with long acting testosterone injection (Nebido) i.m. in hypogonadal patients. Int J Androl 28(suppl 1):53
19.
Yassin A, Saad F. Improvement of sexual functions in men with late onset hypogonadism treated with testosterone only. J Sex Med 2006(September 2006)
20.
Aversa A, Isidori AM, Spera G, Lenzi A, Fabbri A (2003) Androgens improve cavernous vasodilation and response to sildenafil in patients with erectile dysfunction. Clin Endocrinol (Oxf) 58(5):632–8CrossRef
21.
Burnett A (2004) Novel nitric oxide signaling mechanisms regualte the erectile response. Int J Impot Res 16(suppl 1):15–19CrossRef
22.
Traish AM, Guay AT (2006) Are androgens critical for penile erections in humans? Examining the clinical and preclinical evidence. J Sex Med 3(3):382–404; discussion 404–407
23.
Traish AM, Toselli P, Jeong SJ, Kim NN (2005) Adipocyte accumulation in penile corpus cavernosum of the orchiectomized rabbit: a potential mechanism for veno-occlusive dysfunction in androgen deficiency. J Androl 26(2):242–248PubMed
24.
Morales A, Buvat J, Gooren LJ, Guay AT, Kaufman JM, Tan HM (2004) Endocrine aspects of sexual dysfunction in men. J Sex Med 1(1):69–81CrossRefPubMed
25.
Wespes E, Amar E, Hatzichristou D, Hatzimouratidis K, Montorsi F, Pryor J (2006) EAU Guidelines on erectile dysfunction: an update. Eur Urol 49(5):806–815CrossRefPubMed
Metadata
Title
Treatment of sexual dysfunction of hypogonadal patients with long-acting testosterone undecanoate (Nebido®)
Authors
Aksam A. Yassin
Farid Saad
Publication date
01-12-2006
Publisher
Springer-Verlag
Published in
World Journal of Urology / Issue 6/2006
Print ISSN: 0724-4983
Electronic ISSN: 1433-8726
DOI
https://doi.org/10.1007/s00345-006-0120-0

Other articles of this Issue 6/2006

World Journal of Urology 6/2006 Go to the issue

Topic Paper

Significance of hypogonadism in erectile dysfunction

Topic Paper

Understanding the needs and objectives of erectile dysfunction patients

Original Article

Colonization of internal ureteral stent and bacteriuria

Topic Paper

Management of ejaculatory duct obstruction: etiology, diagnosis, and treatment

Topic Paper

Potential future options in the pharmacotherapy of female sexual dysfunction

Topic Paper

Retarded ejaculation